Coloplast A/S: FDA filings under this applicant name
FDA lists 72 510(k) clearances under 2 spellings of the applicant name “Coloplast A/S” (first 1983, latest 2026), across 30 product codes in 3 review panels. Median 510(k) review time under this name: 76 days. Since 2017 the median was 103 days, against 162 days for all cleared 510(k)s in the same product codes. Related companies, subsidiaries and acquired businesses that file under other applicant names are counted on their own pages, not here.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 8 | 126 |
| 2013 | 3 | 83 |
| 2014 | 2 | 84 |
| 2015 | 4 | 81 |
| 2016 | 0 | — |
| 2017 | 0 | — |
| 2018 | 2 | 76 |
| 2019 | 0 | — |
| 2020 | 1 | 256 |
| 2021 | 0 | — |
| 2022 | 1 | 116 |
| 2023 | 1 | 232 |
| 2024 | 0 | — |
| 2025 | 0 | — |
| 2026 | 1 | 20 |
Review time against the same product codes
Since 2017, 510(k)s cleared under the name Coloplast A/S took a median 103 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 162 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| EXB | Collector, Ostomy | 11 | 11 |
| FRO | Dressing, Wound, Drug | 6 | 6 |
| KMF | Bandage, Liquid | 5 | 5 |
| KNX | Collector, Urine, (And Accessories) For Indwelling Catheter | 5 | 5 |
| FED | Endoscopic Access Overtube, Gastroenterology-Urology | 4 | 4 |
| KNT | Tubes, Gastrointestinal (And Accessories) | 4 | 4 |
| OTM | Mesh, Surgical, For Stress Urinary Incontinence, Male | 4 | 4 |
| GBM | Catheter, Urethral | 3 | 3 |
| OTO | Mesh, Surgical, Synthetic, Urogynecologic, For Apical Vaginal And Uterine Prolapse, Transabdominally Placed | 3 | 3 |
| EXD | Irrigator, Ostomy | 2 | 2 |
Plus 20 more product codes.
Review panels
Most recent Coloplast A/S 510(k) clearances
| 510(k) | Device | Product code | Decision date | Review days |
|---|---|---|---|---|
| K262045 | Luja Soft | EZD | 2026-07-07 | 20 |
| K221874 | Altis Single Incision Sling System | PAH | 2023-02-15 | 232 |
| K220420 | Saffron Fixation System | PBQ | 2022-06-10 | 116 |
| K191536 | Biatain Silicone Ag | FRO | 2020-02-21 | 256 |
| K181811 | ReTrace Ureteral Access Sheath | FED | 2018-09-07 | 63 |
| K173527 | Digitex Delivery Device | PWI | 2018-02-12 | 90 |
| K140310 | Peristeen Anal Irrigation System | KNT | 2015-09-03 | 573 |
| K150935 | SpeediCath Compact Eve | GBM | 2015-07-02 | 86 |
| K150927 | Orchestra Hydrophilic Guidewire standard angled, Orchestra Hydrophilic Guidewire straight stiff, Orchestra Hydrophilic Guidewire angled stiff,Orchestra Hydrophilic Guidewire standard straight, Orchestra Hydrophilic Guidewire straight stiff | OCY | 2015-05-27 | 51 |
| K143182 | Speedicath Compact Male | GBM | 2015-01-20 | 76 |
62 earlier clearances. See the full list in Caduvo.
Recalls
FDA recall records list no recalls under a recalling firm named Coloplast A/S.
2 product recalls in 2 recall events filed under other recalling-firm names cite a 510(k) or PMA held under this applicant name; 0 initiated in the last five years. Most often: Coloplast Manufacturing US, LLC (2).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to this applicant name by name only (same normalization), so related entities that recall under another name are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
An industry sponsor named Coloplast A/S is the lead sponsor of 122 device studies on ClinicalTrials.gov (3 active or recruiting). Most recent:
- NCT07376421: Clinical Investigation Exploring a Newly Developed Ostomy Baseplate (Completed, started 2026-01-24)
- NCT07126327: Peristeen Light Explorative Clinical Investigation (Completed, started 2025-11-10)
- NCT07316530: Clinical Investigation Exploring a Newly Developed Ostomy Baseplate. (Completed, started 2025-11-03)
- NCT07146035: Feasibility of a Newly Developed Ostomy Prototype (Not yet recruiting, started 2025-08-25)
- NCT06985888: New Coating for Urinary Intermittent Catheters (Completed, started 2025-05-06)
FDA spellings included
FDA records this applicant under 2 spellings (case, punctuation and legal-suffix variants of one name); this page adds them up. Filings per spelling:
- Coloplast A/S (71)
- Coloplast A.S. (1)
Other FDA applicant names starting with the same word
FDA records these as separate applicants. Some may belong to the same corporate group and some may not; their filings are not included in the counts above.
- Coloplast Corp. (71 510(k)s)
- Coloplast Manufacturing Us, LLC (4 510(k)s)
Frequently asked questions
How many FDA 510(k) clearances are listed under Coloplast A/S?
FDA lists 72 510(k) clearances under 2 spellings of the applicant name “Coloplast A/S” (first 1983, latest 2026), across 30 product codes in 3 review panels. Filings under other applicant names, such as subsidiaries, are not included.
How long has FDA taken to clear 510(k)s filed by Coloplast A/S?
The median time from FDA receipt to decision across 510(k)s cleared under the name Coloplast A/S is 76 days. Since 2017: 103 days, versus 162 days for all cleared 510(k)s in the same product codes.
Which FDA product codes appear under Coloplast A/S?
The most frequent FDA product codes under this applicant name are EXB (Collector, Ostomy, 11); FRO (Dressing, Wound, Drug, 6); KMF (Bandage, Liquid, 5).
Next steps
- See all 72 Coloplast A/S clearances with predicates and recalls
- Run predicate analysis for product code EXB, Coloplast A/S's most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this data. Data and corrections policy.